Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
European Journal of Nuclear Medicine and Molecular Imaging|January 14, 2017
The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimatesLorenza Scarpa, Sabine Buxbaum, Dorota Kendler, et al.
Urology|February 3, 2007
Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancerAndreas P Berger, Martina Deibl, Alexander Strasak, et al.
BJU International|October 18, 2005
Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunctionAndreas P Berger, Martina Deibl, Nicolai Leonhartsberger, et al.
European Urology Open Science|December 24, 2025
Integration of Darolutamide in the Treatment Landscape for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis of Efficacy and SafetyFelix Melchior, Magdalena Koett, Felix Keller, et al.
Clinical Genitourinary Cancer|May 9, 2025
The Clinical Trajectory of Prostate Cancer Patients Harboring Rare Histological Subtypes-A Retrospective Cohort TrialNastasiia Artamonova, Leon Galleé, Hannes Neuwirt, et al.
BJU International|February 12, 2008
Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate-specific antigen level: is there a difference?Alexandre E Pelzer, Daniela Colleselli, Jasmin Bektic, et al.
BJU International|March 18, 2008
Clinical and pathological features of screen vs non-screen-detected prostate cancers: is there a difference?Alexandre E Pelzer, Daniela Colleselli, Jasmin Bektic, et al.
European Urology|August 30, 2005
Are transition zone biopsies still necessary to improve prostate cancer detection? Results from the tyrol screening projectAlexandre E Pelzer, Jasmin Bektic, Andreas P Berger, et al.
BJU International|January 15, 2008
Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0-10.0 ng/mLAlexandre E Pelzer, Daniela Colleselli, Jasmin Bektic, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 22, 2019
Correction to: The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-upJohanna Maffey-Steffan, Lorenza Scarpa, Anna Svirydenka, et al.
Pageof 8